AI-generated research brief — verify at source
mRNA-1083 Combined Flu–COVID Vaccine Meets Noninferiority and Superiority Thresholds in Adults Over 50
In a phase 3 randomized trial of 2,022 Japanese adults aged 50 and older, a single injection of the combination mRNA vaccine mRNA-1083 produced immune responses against all evaluated influenza strains and SARS-CoV-2 that were noninferior to separate licensed vaccines, and superior in the overall study population, with responses persisting at six months and no cases of myocarditis, pericarditis, or intervention-related serious adverse events. These results indicate that combining influenza and SARS-CoV-2 antigens in one mRNA formulation does not compromise immunogenicity relative to receiving two distinct licensed vaccines.
What Was Studied
The trial investigated whether mRNA-1083, an mRNA-based multicomponent vaccine encoding both seasonal influenza and SARS-CoV-2 antigens, could elicit immune responses at Day 29 that were noninferior — and potentially superior — to those produced by a Japan-licensed influenza hemagglutinin (HA) vaccine combined with the separate mRNA-1273 COVID-19 vaccine. The central question was whether a single injection could replace a two-vaccine regimen without sacrificing immunological performance in adults at elevated risk of severe disease.
How It Was Studied
This was Part 1 (Japan) of a larger phase 3, Asia-Pacific, randomized, observer-blind controlled trial registered under NCT06694389. A total of 2,022 adults aged 50 years or older were enrolled and randomized in a 1:1 ratio; 2,013 ultimately received a study intervention. Participants were assigned either mRNA-1083 plus a saline placebo or the Japan-licensed influenza HA vaccine plus mRNA-1273 as an active comparator regimen. Immune responses were assessed at Day 29 as the primary immunogenicity endpoint, with a durability follow-up assessment extending to Day 181, approximately six months post-vaccination.
What Was Observed
- Noninferiority across all strains in the full population: At Day 29, mRNA-1083 produced immune responses against all evaluated influenza strains and SARS-CoV-2 that were statistically noninferior to those generated by the two-vaccine comparator regimen, meeting the primary endpoint across the entire enrolled population.
- Noninferiority confirmed in high-risk subgroups: Among participants defined as high-risk — those aged 65 and older, and those aged 60 to under 65 with at least one comorbidity — mRNA-1083 demonstrated noninferior responses for comparator-matched influenza strains and SARS-CoV-2, suggesting the combined vaccine performs consistently even in groups with greater disease vulnerability.
- Superiority demonstrated in the overall population: Beyond meeting noninferiority criteria, mRNA-1083 demonstrated superiority over the active comparators for comparator-matched influenza strains and for SARS-CoV-2 in the overall study population, indicating that immune response magnitudes from the combination vaccine exceeded those from the separate licensed vaccines.
- Durable responses and favorable safety through six months: At Day 181, antibody responses remained above pre-vaccination baseline levels and were comparable to or numerically higher than those seen with active comparators. Most solicited adverse reactions were mild to moderate (grade 1 or 2), with no cases of myocarditis or pericarditis and no serious adverse events or deaths attributed to the study intervention.
Why This Matters
Simultaneous protection against two major respiratory pathogens through a single injection could meaningfully simplify seasonal vaccination programs for adults aged 50 and older, reducing the logistical and compliance barriers associated with administering separate vaccines. The trial directly demonstrates that combining influenza and SARS-CoV-2 mRNA antigens into one formulation does not dilute the immune response to either pathogen, and in fact surpasses the separate licensed vaccines in the overall population. The six-month durability data further support the practical relevance of mRNA-1083 within an annual vaccination cycle.
How to Read This Result
This is a high-quality randomized controlled trial with a substantial sample size and a rigorous active comparator design, and the findings are consistently positive across both primary and secondary immunogenicity endpoints; however, the study reports surrogate immune response measures rather than clinical efficacy against influenza or COVID-19 disease, and durability beyond six months remains uncharacterized.
Limitations
The abstract does not explicitly report study limitations.